Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | PHASE1 | RECRUITING | 280 | — | — | Feb 11, 2026 | Dec 31, 2029 | Mar 12, 2026 | 1 | China |
AEs are assessed based on NCI CTCAE v6.0.
MTD of 7MW3711
RED of 7MW3711
| Arm | Type | Description |
|---|---|---|
| Phase 1b: Safety run-in | EXPERIMENTAL | Multiple dose levels of 7MW3711 will be explored in combination with JS207 with or without Chemotheray administered intravenously (IV) at a fixed dose as specified in the protocol. |
| Phase 2: Dose expansion | EXPERIMENTAL | 7MW3711 will be administered at the selected RDE in combination with JS207 with or without Chemotheray administered IV at a fixed dose as specified in the protocol. |
| Name | Type | Description |
|---|---|---|
| 7MW3711 | DRUG | 7MW3711 will be administered as IV infusion. |
| JS207 | DRUG | JS207 will be administered as IV infusion. |
| Cisplatin | DRUG | Cisplatin will be administered as IV infusion. |
| Carboplatin | DRUG | Carboplatin will be administered as IV infusion. |
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 2. Life expectancy of at least 3 months as assessed by the Investigator. 3. Phase 1b: Histologically or cytologically confirmed locally advanced or metastatic solid tumor, progressive after last treatment...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |